Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their applications from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways of Small Nucleic Acid Drug Development - ASO and siRNA represent two distinct technological pathways, with ASO focusing on RNA degradation and splicing regulation, while siRNA employs the RISC mechanism for mRNA degradation [12][26] Chemical Modifications and Stability - The report outlines four generations of chemical modifications that enhance the stability and specificity of ASO, which are crucial for their therapeutic efficacy [32][36] Delivery Breakthroughs - The report identifies the challenges of delivering small nucleic acids across cellular barriers, emphasizing the need for effective delivery systems to overcome these obstacles [40][43] Safety Optimization - Innovations in safety management, such as the development of antidotes for siRNA and toxicity control for ASO, are essential for supporting long-term use and chronic disease management [3][62] Commercialization and Boundary Expansion - The industry is moving from liver-targeted therapies to exploring delivery strategies for other tissues, with companies like Alnylam aiming for multi-organ delivery by 2030 [60][61]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The report highlights the ongoing collaboration between GSK and Chinese company Frontier Bio in the siRNA field, indicating that Chinese enterprises are gaining international recognition for their R&D capabilities [6][7] - The pharmaceutical sector saw a 0.5% increase, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th among 31 sub-industries [8][22] - The report recommends focusing on innovative drugs and their supply chains, including CXO and research services, as well as emerging industries like AI and brain-machine interfaces [9] Summary by Sections GSK Collaboration and Market Trends - GSK has been actively engaging in partnerships related to small nucleic acids, with significant pipelines in ASO and siRNA. Notably, GSK's collaboration with Frontier Bio involves a total transaction value of up to $1.003 billion for two pipelines [6][7][18] - The report notes that GSK's recent partnerships reflect the growing technical strength and platform value of Chinese companies in the small nucleic acid drug development sector [7][17] Market Performance - In the week of February 4, 2026, the pharmaceutical sector increased by 0.5%, with the medical consumables sector showing the highest growth at 3.99%. Conversely, the medical R&D outsourcing sector experienced the largest decline at -2.2% [8][22][23] - Monthly data indicates that since the beginning of 2026, the overall market has been on an upward trend, with various sectors performing differently [22] Recommendations - The report continues to favor innovative drugs and their associated industries, recommending specific companies such as Heng Rui Medicine, WuXi AppTec, and others for investment [9][26] - Weekly recommendations include companies like Bai Li Tian Heng and Kanglong Huacheng, indicating a strategic focus on firms with strong growth potential in the pharmaceutical sector [9]